Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14670
Abstract: Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. This post‐hoc study evaluated effects of empagliflozin on risk for non‐alcoholic fatty liver disease‐related steatosis and fibrosis, as well as the relationship between risk… read more here.
Keywords: empagliflozin markers; relationship; cardiorenal outcomes; steatosis fibrosis ... See more keywords